Bayer sues COVID vaccine makers over mRNA technology

Reuters01-07
UPDATE 1-Bayer sues COVID vaccine makers over mRNA technology

Adds links to lawsuits in paragraphs 2 and 3, Moderna response and requests for defendant comments in paragraph 4

By Blake Brittain

Jan 6 (Reuters) - Bayer's BAYGn.DE Monsanto sued COVID-19 vaccine makers Pfizer PFE.N, BioNTech 22UAy.DE and Moderna MRNA.O in Delaware federal court on Tuesday for allegedly misusing its messenger RNA technology in manufacturing their vaccines, a Bayer spokesperson confirmed.

The patent infringement lawsuits said the companies copied technology developed by Monsanto in the 1980s for strengthening mRNA in crops in order to stabilize the genetic material used in their vaccines.

Bayer separately filed a similar lawsuit against Johnson & Johnson JNJ.N in New Jersey federal court on Tuesday, arguing that a DNA-based process J&J used in manufacturing its shots infringed the patent.

A Moderna spokesperson said the company is aware of the lawsuit and will defend itself. Spokespeople for Pfizer, BioNTech and Johnson & Johnson did not immediately respond to requests for comment.

Bayer's complaints add to a web of patent lawsuits over the blockbuster COVID shots, which include an ongoing lawsuit filed by Moderna against Pfizer in 2022.

Bayer was not involved in developing COVID vaccines and does not make or sell any version of them. It asked the courts for an unspecified amount of monetary damages and said it was not seeking to block the companies from manufacturing their vaccines.

Pfizer and BioNTech earned more than $3.3 billion in revenue from global sales of their vaccine Comirnaty in 2024, while Moderna earned $3.2 billion from its Spikevax, according to company reports, a fraction of their sales at the height of the pandemic.

Johnson & Johnson stopped selling its COVID vaccine in the United States in 2023.

Bayer's lawsuits said Monsanto scientists pioneered technology in the 1980s for reducing mRNA instability to make more pest-resistant crops. Bayer alleged that Pfizer and Moderna utilized technology for improving the stability of mRNA that infringes one of its patents.

(Reporting by Blake Brittain in WashingtonEditing by Bill Berkrot)

((blake.brittain@tr.com; +1 (202) 938-5713))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment